Skip to main content

Table 1 Clinicopathological factors and the expression of MUC4/Y in 108 patients with PDAC

From: Specific-detection of clinical samples, systematic functional investigations, and transcriptome analysis reveals that splice variant MUC4/Y contributes to the malignant progression of pancreatic cancer by triggering malignancy-related positive feedback loops signaling

Category N(%) MUC4/Y
   Mean Median(range) PValue
Age(y)     
<60 47 (43.52) 0.0076 0.0010(0.0000-0.0829) 0.689
≥60 61 (56.48) 0.0112 0.0012(0.0000-0.2350)  
Gender     
 Male 61 (56.48) 0.0117 0.0013(0.0000-0.2350) 0.228
 Female 47 (43.52) 0.0070 0.0010(0.0000-0.0787)  
Location of tumor     
 Head 72 (66.67) 0.0071 0.0010(0.0000-0.0842) 0.494
 Body and tail 36 (33.33) 0.0147 0.0015(0.0000-0.2350)  
Size of tumor     
≤2 cm 22 (20.37) 0.0074 0.0010(0.0000-0.0682) 0.647
>2 cm 86 (79.63) 0.0102 0.0011(0.0000-0.2350)  
Nerve infiltration     
 No 38 (35.19) 0.0098 0.0007(0.0000-0.0842) 0.137
 Yes 70 (64.81) 0.0096 0.0012(0.0000-0.2350)  
Differentiation     
 Well 15 (13.89) 0.0267 0.0012(0.0000-0.2350) 0.979
 Moderate 83 (76.85) 0.0071 0.0011(0.0000-0.0842)  
 Poor 10 (9.26) 0.0055 0.0011(0.0001-0.0340)  
TNMa staging     
 IA + IB 15 (13.89) 0.0009 0.0006(0.0000-0.0040) 0.001*
 IIA 33 (30.56) 0.0056 0.0015(0.0001-0.0682)  
 IIB 46 (42.59) 0.0069 0.0008(0.0000-0.0842)  
 III + IV 14 (12.96) 0.0380 0.0076(0.0003-0.2350)  
Serum CA19-9b level     
 ≤39KU/l 31 (28.70) 0.0155 0.0009(0.0000-0.2350) 0.965
 >39KU/l 77 (71.30) 0.0073 0.0011(0.0000-0.8423)  
Serum CA50c level     
 ≤25KU/l 49 (45.37) 0.0152 0.0009 (0.0000-0.2350) 0.894
 >25KU/l 59 (54.63) 0.0050 0.0011(0.0000-0.0829)  
Serum CEAd level     
 ≤5 μg/l 64 (59.26) 0.0093 0.0010(0.0000-0.0842) 0.557
 >5 μg/l 44 (40.74) 0.0101 0.0011(0.0000-0.2350)  
  1. TNMa, tumor-node-metastasis; CA19-9b, carbohydrate antigen 19–9; CA50c, carbohydrate antigen 50; CEAd, carcinoembryonic antigen; *P <0.05.